GPCR therapeutic monoclonal antibodies · 30. April 2022
SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.
GPCR therapeutic monoclonal antibodies · 05. April 2022
SYnAbs discovers antibodies to transmembrane proteins including GPCR chemokine receptors thanks to unique peptide and cell immunization technologies
GPCR therapeutic monoclonal antibodies · 19. March 2022
SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins
Secondary monoclonal antibodies · 05. March 2022
SYnAbs mouse anti-rat light chains to monitore immune isotypic response, quantify circulating rat therapeutic antibody candidates, and easily purify all rat isotypes without cross-binding to bovine serum immunoglobulins
Secondary monoclonal antibodies · 26. February 2022
SYnAbs rat anti-mouse IgG to monitore immune isotypic response to infections and vaccines, better comprehend B-cells & T-cells interactions and pathology-related mechanisms in transgenic mouse models
Receptor tyrosine kinase therapeutic monoclonal antibodies · 06. February 2022
SYnAbs generates custom therapeutic monoclonal antibodies to receptor tyrosine kinases (RTKs) thanks to proprietary technologies and unique expertise
Secondary monoclonal antibodies · 21. January 2022
SYnAbs unique highly specific anti-human IgG4 monoclonal antibodies without cross-reaction to the other human isotypes subclasses IgG1, IgG2, and IgG3.
New primary monoclonal antibodies · 13. January 2022
SYnAbs unique monoclonal antibodies are highly specific to hemoglobin mutations HbA, HbC, HbE, HbS, and pan-Hb to detect sickle cell disease.
Immunoglobulin SuperFamily (IgSF) therapeutic antibodies · 04. December 2021
SYnAbs unique therapeutic rat monoclonal antibodies targeting CD2 giving birth to Siplizumab and LO-CD2b for T cell depletion. Unique DNA, syngeneic cell immunization strategies to generate monoclonals against transmembrane proteins.
New primary monoclonal antibodies · 30. October 2021
Benefit from natural in-vivo maturation to get access to highly specific and high affinity rat monoclonal antibodies for therapeutic use targeting transmembrane proteins GPCR, ion channels and other complex epitopes
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
+32 (0)71/374.880
BE 0637.716.206
